Peptic Ulcers Therapeutics Pipeline Review H1 2017

June 19, 2017 /MarketersMEDIA/ —

Peptic Ulcers Therapeutics Pipeline Review H1 2017 report provides an overview of the Peptic Ulcers (Gastrointestinal) pipeline landscape. The Peptic Ulcers (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 5 and 10 respectively.

Inquire for Complete PDF Report @ http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1057939

Description of Report:

Peptic Ulcers - Pipeline Review H1 2017 provides comprehensive information on the therapeutics under development for Peptic Ulcers (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Peptic Ulcers Therapeutics Pipeline Review H1 2017 report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Key Companies Analyzed In Report:

Astellas Pharma Inc, Boryung Pharmaceutical Co Ltd, ChoDang Pharm Co Ltd, Daewoong Pharmaceutical Co Ltd, Kukje Pharmaceutical Industry Co Ltd, RaQualia Pharma Inc, Sequella Inc, Sinil Pharmaceutical Co Ltd, XuanZhu Pharma Co Ltd.

Peptic Ulcers Drug Profile Discussed:

(lafutidine + irsogladine maleate), (lansoprazole + omeprazole), anaprazole sodium, ASP-6537, BGC-001, cholesteryl glucoside, DWJ-1386, DWJ-206, DWP-14012, KJ-14001, PMKS-005, RQ-00000774, SFR-9X0123, SI-001002, Small Molecule to Inhibit Potassium Transporting ATPase Alpha Chain 1 Inhibitor for Peptic Ulcers and Reflux Esophagitis, Small Molecules for Gastric Ulcers, SQ-109, tegoprazan.

Scope:

The pipeline guide provides a snapshot of the global therapeutic landscape of Peptic Ulcers (Gastrointestinal) and reviews pipeline therapeutics for Peptic Ulcers (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. This Peptic Ulcers Therapeutics Pipeline covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages and also features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. key companies involved in Peptic Ulcers (Gastrointestinal) therapeutics and enlists all their major and minor projects are reviewed in this report.

Get Discount On Report @ http://www.reportsnreports.com/contacts/discount.aspx?name=1057939

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Identify and understand important and diverse types of therapeutics under development for Bullous Pemphigoid. Identify potential new clients or partners in the target demographic. Develop strategic initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics. Devise corrective measures for pipeline projects by understanding Bullous Pemphigoid pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Buy Report: http://www.reportsnreports.com/purchase.aspx?name=1057939 .

List of Tables

• Number of Products under Development for Peptic Ulcers, H1 2017
• Number of Products under Development by Companies, H1 2017
• Products under Development by Companies, H1 2017
• Number of Products by Stage and Target, H1 2017
• Number of Products by Stage and Mechanism of Action, H1 2017
• Number of Products by Stage and Route of Administration, H1 2017
• Number of Products by Stage and Molecule Type, H1 2017
• Peptic Ulcers - Pipeline by Astellas Pharma Inc, H1 2017
• Peptic Ulcers - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017
• Peptic Ulcers - Pipeline by ChoDang Pharm Co Ltd, H1 2017
• Peptic Ulcers - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
• Peptic Ulcers - Pipeline by Kukje Pharmaceutical Industry Co Ltd, H1 2017
• Peptic Ulcers - Pipeline by RaQualia Pharma Inc, H1 2017
• Peptic Ulcers - Pipeline by Sequella Inc, H1 2017
• Peptic Ulcers - Pipeline by Sinil Pharmaceutical Co Ltd, H1 2017
• Peptic Ulcers - Pipeline by XuanZhu Pharma Co Ltd, H1 2017
• Peptic Ulcers - Dormant Projects, H1 2017
• Peptic Ulcers - Dormant Projects, H1 2017 (Contd..1), H1 2017
• Peptic Ulcers - Discontinued Products, H1 2017

List of Figures

• Number of Products under Development for Peptic Ulcers, H1 2017
• Number of Products under Development by Companies, H1 2017
• Number of Products by Top 10 Targets, H1 2017
• Number of Products by Stage and Top 10 Targets, H1 2017
• Number of Products by Mechanism of Actions, H1 2017
• Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
• Number of Products by Stage and Routes of Administration, H1 2017
• Number of Products by Molecule Types, H1 2017
• Number of Products by Stage and Molecule Types, H1 2017

About Us:

Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Contact Us:
Ritesh Tiwari
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
India.
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com

Contact Info:
Name: Ritesh Tiwari
Email: Send Email
Organization: ReportsnReports
Address: Pune
Phone: +1-888-391-5441
Website: http://www.reportsnreports.com/reports/1057939-peptic-ulcers-pipeline-review-h1-2017.html

Release ID: 208748